Related Experiment Video
Updated: Jan 22, 2026

Electrochemical Preparation of Poly3,4-Ethylenedioxythiophene Layers on Gold Microelectrodes for Uric Acid-Sensing Applications
Published on: July 28, 2021
Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients
Jing Wu1, Yu-Ping Zhang1, Yuan Qu1
1Department of Rheumatology and Clinical Immunology, ZhuJiang Hospital, Southern Medical University, Guangzhou, China.
Insights
Uric acid-lowering therapy can improve hyperlipidemia in gout patients. Febuxostat demonstrated superior efficacy in reducing cholesterol and triglyceride levels compared to allopurinol and benzbromarone.
Area of Science:
- Rheumatology
- Cardiology
- Pharmacology
Background:
- Gout patients often present with hyperlipidemia, a condition requiring management.
- Uric acid-lowering therapy (UALT) is standard for gout, but its impact on lipid profiles is of interest.
Purpose of the Study:
- To evaluate the effects of Uric Acid-Lowering Therapy (UALT) on hypercholesterolemia and hypertriglyceridemia in patients with gout.
- To compare the efficacy of febuxostat, allopurinol, and benzbromarone in managing dyslipidemia in this population.
Main Methods:
- Retrospective study of 124 gout patients with hyperlipidemia from January 2015 to December 2017.
- Patients received either febuxostat (52), allopurinol (29), or benzbromarone (43).
- Serum cholesterol and triglyceride levels were analyzed after 8-10 weeks of UALT.
Main Results:
- All UALT agents showed mild effects on serum cholesterol and triglyceride levels.
- Febuxostat significantly reduced both cholesterol and triglyceride levels in patients not on lipid-lowering medication.
- Allopurinol and benzbromarone showed modest reductions in triglycerides, with no significant impact on cholesterol.
Conclusions:
- UALT offers benefits for hyperlipidemia management in gout patients.
- Febuxostat is more effective than allopurinol and benzbromarone in improving lipid profiles in gout patients with hyperlipidemia.
Aim:
To investigate the effects on hypercholesterolemia and hypertriglyceridemia in gouty patients receiving uric acid-lowering therapy (UALT).
Methods:
A retrospective study was performed from January 2015 to December 2017 in gouty patients receiving UALT. A total of 124 gouty patients with hypercholesterolemia or hypertriglyceridemia who were administered UALT were monitored. Of the 124 patients with gout, 52 were treated with febuxostat, 29 were treated with allopurinol, and 43 were treated with benzbromarone. Cholesterol and triglyceride levels were recorded and analyzed following treatment for 8-10 weeks.
Results:
We compared the efficacy of febuxostat, allopurinol, and benzbromarone. All therapies mildly influenced serum cholesterol and triglyceride levels. Febuxostat significantly decreased cholesterol and triglyceride levels in patients who did not receive lipid-lowering therapy. Allopurinol and benzbromarone modestly decreased triglyceride levels, but cholesterol levels were unaffected.
Conclusion:
Uric acid-lowering therapy benefits hyperlipidemia in gouty patients. Febuxostat effectively improved serum cholesterol and triglyceride levels compared to allopurinol and benzbromarone in patients with gout.
More Related Videos
05:52Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy
Published on: November 17, 2023
10:02Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
Published on: October 3, 2020
Related Concept Videos
Vapor Pressure Lowering
Self-Efficacy
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Gene Therapy
Amino acids
Mixtures of Acids
A Mixture of a Strong Acid and a Weak Acid
In a mixture of a strong acid and a weak acid, the strong acid dissociates completely and becomes a source of almost all the hydronium ions...